EUVIMEDEUVIMED entdecken
Crossref

Preclinical safety evaluation of the synthetic human-milk-identical Ganglioside GM3 (d18:1/18:0, Neu5Ac)

Elisabete Maciel, Narinder Barraclough, Gerhard Gans

Food and Chemical Toxicology · 2027-01 · 219 · 116474

DOI: 10.1016/j.fct.2026.116474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2027-01. Verfasst von Elisabete Maciel und 2 weiteren Autor:innen. Beteiligte Einrichtung: CarboCode SA, Parque Tecnologico de Cantanhede, Nucleo-04, 3060-197, Cantanhede, Portugal. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Commercial infant formula is expected to mimic human breast milk, therefore providing optimum nutrition to the infant. Supplementation with synthesised ganglioside GM3 (d18:1/18:0, Neu5Ac) has been found to be chemically identical to that found in human breast milk. Standard in vitro genotoxicity tests were performed and GM3 was found to be non-mutagenic in the in vitro Ames and Micronucleus Assays. To investigate the toxicological profile in a model representative of the intended target population GM3 was administered orally via gavage at dose levels of 0, 500, 1000 and 1300 mg GM3/kg bw per day, in a 90-day toxicity study, adapted to be performed in the juvenile rat from Postnatal Day 7. Oral administration up to 1300 mg GM3/kg bw per day over 90 consecutive days was not associated with any adverse effect based on clinical observations, body weight gain, food consumption, physical, functional and neurobehavioral development, ophthalmoscopy, clinical pathology, organ weights and histopathology findings. Based on the 90-day study a No Observed Adverse Effect Level of 1300 mg GM3/kg bw per day for both male and female rats was established. These findings support the safety of GM3 as a food ingredient for infants and adults in different food applications.

Schlagwörter

Stichwörter der Autor:innen

FoodGavageHuman milk gangliosidesJuvenile RatMutagenicitySafetySub-chronic toxicity

Autor:innen und Institutionen

  • CarboCode SA, Parque Tecnologico de Cantanhede, Nucleo-04, 3060-197, Cantanhede, Portugal.
  • Labcorp, Harrogate, UK.
  • CarboCode SA, Parque Tecnologico de Cantanhede, Nucleo-04, 3060-197, Cantanhede, Portugal. Electronic address: gerhard.gans@carbocode.com.

Zitieren

APA

Maciel, E., Barraclough, N., & Gans, G. (2027). Preclinical safety evaluation of the synthetic human-milk-identical Ganglioside GM3 (d18:1/18:0, Neu5Ac). Food and Chemical Toxicology, 219, 116474. https://doi.org/10.1016/j.fct.2026.116474

Vancouver

Maciel E, Barraclough N, Gans G. Preclinical safety evaluation of the synthetic human-milk-identical Ganglioside GM3 (d18:1/18:0, Neu5Ac). Food and Chemical Toxicology. 2027;219:116474. doi:10.1016/j.fct.2026.116474

BibTeX
@article{Maciel2027,
  author = {Maciel, Elisabete and Barraclough, Narinder and Gans, Gerhard},
  title = {Preclinical safety evaluation of the synthetic human-milk-identical Ganglioside GM3 (d18:1/18:0, Neu5Ac)},
  journal = {Food and Chemical Toxicology},
  year = {2027},
  volume = {219},
  pages = {116474},
  doi = {10.1016/j.fct.2026.116474}
}
Kostenlos starten →